{
  "success": true,
  "sourceFile": "C:\\Users\\panik\\Documents\\GitHub\\Protcol2USDMv3\\input\\trial\\NCT02407236_UNIFI\\NCT02407236_UNIFI_SAP.pdf",
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39
  ],
  "modelUsed": "gemini-3-flash-preview",
  "sapData": {
    "analysisPopulations": [
      {
        "id": "pop_1",
        "name": "Primary Population",
        "text": "Subjects who are in clinical response to IV ustekinumab during induction will comprise the primary population in the maintenance study; this population will include the following: Subjects who are randomized to receive ustekinumab at Week 0 of the induction study and are in clinical response at I-8; Subjects who are randomized to receive placebo at Week 0 of the induction study and are not in clinical response at I-8, but are in clinical response at I-16 after receiving an induction dose of IV ustekinumab (~6 mg/kg) at I-8. Note that subjects who are delayed clinical responders to ustekinumab induction (i.e., the subjects who are randomized to ustekinumab at Week 0 of the induction study, not in clinical response at I-8 but are in clinical response at I-16 after receiving 1 dose of ustekinumab 90 mg SC at I-8) will not be included in the primary population.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "Primary Population",
        "populationDescription": "Subjects who are in clinical response to IV ustekinumab during induction will comprise the primary population in the maintenance study; this population will include the following: Subjects who are randomized to receive ustekinumab at Week 0 of the induction study and are in clinical response at I-8; Subjects who are randomized to receive placebo at Week 0 of the induction study and are not in clinical response at I-8, but are in clinical response at I-16 after receiving an induction dose of IV ustekinumab (~6 mg/kg) at I-8. Note that subjects who are delayed clinical responders to ustekinumab induction (i.e., the subjects who are randomized to ustekinumab at Week 0 of the induction study, not in clinical response at I-8 but are in clinical response at I-16 after receiving 1 dose of ustekinumab 90 mg SC at I-8) will not be included in the primary population.",
        "criteria": "In clinical response to IV ustekinumab induction (either at I-8 following IV induction or at I-16 following I-8 IV rescue) AND not a delayed responder receiving SC at I-8"
      },
      {
        "id": "pop_2",
        "name": "Non-randomized Analysis Set",
        "text": "Includes subjects entering the maintenance study who will not be part of the primary population: Subjects who are in clinical response to placebo IV induction will receive placebo SC; Subjects who are delayed responders to ustekinumab induction will receive ustekinumab 90 mg SC q8w.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "Non-randomized Analysis Set",
        "populationDescription": "Includes subjects entering the maintenance study who will not be part of the primary population: Subjects who are in clinical response to placebo IV induction will receive placebo SC; Subjects who are delayed responders to ustekinumab induction will receive ustekinumab 90 mg SC q8w.",
        "criteria": "Clinical responders to placebo IV induction OR delayed responders to ustekinumab induction (responders at I-16 after SC dose at I-8)"
      },
      {
        "id": "pop_3",
        "name": "Safety Analysis Set",
        "text": "All subjects who receive at least one dose of SC study agent at the M-0 visit or thereafter during the maintenance study.",
        "populationType": "Safety",
        "instanceType": "AnalysisPopulation",
        "label": "Safety",
        "populationDescription": "All subjects who receive at least one dose of SC study agent at the M-0 visit or thereafter during the maintenance study.",
        "criteria": "Received >=1 dose of SC study agent in maintenance study"
      },
      {
        "id": "pop_4",
        "name": "Pharmacokinetics Analysis Set",
        "text": "Subjects with evaluable ustekinumab concentration data from the maintenance study.",
        "populationType": "PK/PD",
        "instanceType": "AnalysisPopulation",
        "label": "PK",
        "populationDescription": "Subjects with evaluable ustekinumab concentration data from the maintenance study.",
        "criteria": "Has evaluable PK samples"
      }
    ],
    "characteristics": [
      {
        "id": "char_1",
        "name": "Clinical remission status at maintenance baseline",
        "code": "CLINICAL_REMISSION_S",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Clinical remission status at maintenance baseline",
        "dataType": "Boolean",
        "instanceType": "Characteristic",
        "description": "Whether the subject is in clinical remission at the start of the maintenance study (yes/no)"
      },
      {
        "id": "char_2",
        "name": "Oral corticosteroid use at maintenance baseline",
        "code": "ORAL_CORTICOSTEROID_",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Oral corticosteroid use at maintenance baseline",
        "dataType": "Boolean",
        "instanceType": "Characteristic",
        "description": "Whether the subject is using oral corticosteroids at the start of the maintenance study (yes/no)"
      },
      {
        "id": "char_3",
        "name": "Induction treatment",
        "code": "INDUCTION_TREATMENT",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Induction treatment",
        "dataType": "String",
        "instanceType": "Characteristic",
        "description": "The specific treatment regimen received during the induction phase (placebo IV, ustekinumab 130 mg IV, or ustekinumab ~6 mg/kg IV)"
      }
    ],
    "summary": {
      "populationCount": 4,
      "characteristicCount": 3
    }
  }
}